Replimune(US:REPL) GlobeNewswire News Roomยท2025-08-01 14:51Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to significant stock losses following a negative FDA response regarding its drug application [3][5][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [3][8]. - The complaint alleges that Replimune and its executives made false or misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5]. Group 2: Impact of FDA Response - On July 22, 2025, Replimune received a Complete Response Letter from the FDA, indicating that the application for RP1 was not approvable in its current form due to inadequacies in the IGNYTE trial [6]. - Following the FDA's announcement, Replimune's stock price fell over 73% during intraday trading on the same day [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].